34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities

MLA

L. Fredrik Jarskog, et al. “34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities.” CNS Spectrums, vol. 24, Feb. 2019, p. 193. EBSCOhost, https://doi.org/10.1017/s1092852919000282.

APA

L. Fredrik Jarskog, Stanislaw Ochudlo, David Stamler, Mat D. Davis, Karen E. Anderson, Rajeev Kumar, Joohi Jimenez-Shahed, Robert A. Hauser, Joseph P. McEvoy, & Hubert H. Fernandez. (2019). 34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. CNS Spectrums, 24, 193. https://doi.org/10.1017/s1092852919000282

Chicago

L. Fredrik Jarskog, Stanislaw Ochudlo, David Stamler, Mat D. Davis, Karen E. Anderson, Rajeev Kumar, Joohi Jimenez-Shahed, Robert A. Hauser, Joseph P. McEvoy, and Hubert H. Fernandez. 2019. “34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities.” CNS Spectrums 24 (February): 193. doi:10.1017/s1092852919000282.